Amber L Hall

Ms. Amber L Hall

Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2026 in Animals
Verified
Journal Article
Open access
PDF file
MLMelissa J Lewis
Melissa J Lewis
EKElizabeth Kawecki-Wright
Elizabeth Kawecki-Wright
Amber L HallAmber L Hall
Amber L Hall
NHNathan P Hall
Nathan P Hall
YQYANG QU
YANG QU
BLB. Duncan Lascelles
B. Duncan Lascelles
Objective, noninvasive biomarkers of joint inflammation or pain are needed for dogs with osteoarthritis (OA). This prospective, observational study investigated whether body surface temperature quantified by infrared thermography was associated with joint pain and/or radiographic osteoarthritis (rOA) in dogs. Using thermal images, 14 regions of interest (ROI) were created for bilateral limb joints and the vertebral column for each dog and the mean temperature was calculated for each ROI. Orthopedic examination and radiographs classified each joint/region as affected or unaffected by rOA, pain, or both, called symptomatic OA (sxOA). Mean temperatures were compared between affected and unaffected joints. Eighteen dogs were enrolled, encompassing analysis of 250 ROI (rOA = 83/250, 33%; pain = 83/250, 33%; sxOA = 61/250, 24%). No temperature differences were detected between affected and unaffected joints for rOA (0.405 °C, 95% CI [−0.204, 1.025 °C]), pain (0.208 °C, 95% CI [−0.390, 0.806 °C]), or sxOA (0.276 °C, 95% CI [−0.344, 0.915 °C]). Elbow and stifle regions were warmer, and the lumbosacral region was cooler than the carpus. Long-haired dogs were cooler than short-coated dogs. Regional temperature variability and haircoat type might hinder detection of OA-related thermal signals. In dogs with OA, findings do not support infrared thermography as a standalone tool to identify affected joints.

19 November 2026 in American Journal of Veterinary Research
Verified
Journal Article
Open access
KTKornelia Tiffinger
Kornelia Tiffinger
JVJavier Benito de la Vibora
Javier Benito de la Vibora
Amber L HallAmber L Hall
Amber L Hall
NHNathan P Hall
Nathan P Hall
RTReece Taylor
Reece Taylor
MEMasataka Enomoto
Masataka Enomoto
Objective: To evaluate the efficacy of an extended-release formulation of buprenorphine HCl (XR-Bup) using objective gait analysis in a canine stifle arthrotomy model. We hypothesized that a single SC injection of XR-Bup would reduce postoperative pain and improve limb function. Methods: In a randomized, blinded, placebo-controlled crossover study design, 8 purpose-bred Beagles underwent 2 unilateral stifle arthrotomies, randomized to XR-Bup for 1 procedure and placebo for the other, separated by a washout period. Kinetic and static ground reaction force data were collected at baseline (pretreatment) and multiple time points up to 72 hours after arthrotomy. Symmetry indices were calculated for ground reaction force variables and compared between groups using a repeated-measures analysis. Results: Overall, symmetry indices of static body weight distribution (%BW distrib ) showed significantly greater limb use symmetry following XR-Bup compared to placebo. There was significant time and treatment interaction ( P = .025) for %BW distrib to the operated limb, with %BW distrib approaching baseline levels more quickly when treated with XR-Bup. Similarly, kinetic variables demonstrated higher limb use in the XR-Bup group, although the treatment effects were not significant. All dogs experienced nausea and hyporexia/anorexia after XR-Bup over 72 hours. Vomiting occurred in 6 of 9 and regurgitation was observed in 8 of 9 arthrotomy cases. Conclusions: XR-Bup treatment was associated with greater limb usage (static and dynamic) at all time points, with data indicating effective pain alleviation in a small cohort of dogs. Clinical Relevance: Although Ethiqa XR may be an alternative option for postoperative pain control, its clinical utility at the dose evaluated in this study may be limited by the occurrence of adverse events.